Patent ReferencesCompressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating Pharmaceutical compositions and methods for producing alpha antagonism Pharmaceutical multiple-units formulation Dosage units for controlled release of active material Sustained release tablets and method of making same Patent #: 4684516 InventorsAssigneeApplicationNo. 273192 filed on 11/18/1988US Classes:424/497, Containing solid synthetic polymers424/494, Cellulose derivatives424/495Ethyl celluloseExaminersPrimary: Page, Thurman K.Attorney, Agent or FirmInternational ClassesA61K 009/16A61K 009/50 Foreign Application Priority Data1987-11-20 IEAbstractA controlled absorption diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming water insoluble synthetic polymer and optionally a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer, when said water soluble polymer is present, being effective to permit release of diltiazem from the pellet at a rate allowing controlled absorption thereof over not less than a twelve hour period following oral administration. The pellet has a dissolution rate in vitro which when measured in a dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXI in 0.05 M KCl at pH 7.0 results in not more than 35% of the total diltiazem being released after 2 hours of measurement. Not more than 60% of the total diltiazem is released after four hours of measurement and 100% of the diltiazem is released no earlier than after 8 hours of measurement in said apparatus. | |